Attached files
| file | filename |
|---|---|
| 10-K - CYTORI THERAPEUTICS, INC. FORM 10K YEAR ENDED 12-31-2009 - PLUS THERAPEUTICS, INC. | form10k_12312009.htm |
| EX-32.1 - EXHIBIT 32.1 SECTION 906 CERTIFICATION - PLUS THERAPEUTICS, INC. | exhibit321_section906cert.htm |
| EX-31.1 - EXHIBIT 31.1 CEO CERTIFICATION - PLUS THERAPEUTICS, INC. | exhibit311_ceocertification.htm |
| EX-31.2 - EXHIBIT 31.2 CFO CERTIFICATION - PLUS THERAPEUTICS, INC. | exhibit312_cfocertification.htm |
|
|
EXHIBIT 23.1
|
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Cytori Therapeutics, Inc.:
We consent to the incorporation by reference in the registration statement (Nos. 333-82074 and 333-122691) on Form S-8 and (Nos. 333-159912, 333-140875, 333-157023, 333-153233 and 333-134129) on Form S-3 of Cytori Therapeutics, Inc. of our reports dated March 12, 2010, with respect to the consolidated balance sheets of Cytori Therapeutics, Inc. and subsidiaries as of December 31, 2009 and 2008, and the related consolidated statements of operations and comprehensive loss, stockholders' equity (deficit), and cash flows for each of the years in the three-year period ended December 31, 2009, the accompanying schedule of valuation and qualifying accounts, and the effectiveness of internal control over financial reporting of Cytori Therapeutics, Inc. and subsidiaries as of December 31, 2009, and to the reference to our firm in Item 6, Selected Financial Data, which reports and reference to our firm appears in the December 31, 2009, annual report on Form 10-K of Cytori Therapeutics, Inc.
Our report on the consolidated financial statements refers to a change in the Company’s method of accounting for certain warrants due to the adoption of a new accounting pronouncement in 2009.
|
/s/ KPMG LLP
|
|
|
San Diego, California
|
|
|
March 12, 2010
|
|